Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 4/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.30 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12405021 | 0.88 | HDAC1 (0.37) | HDAC1HDAC6GRM5RORCAR | |
| SCHEMBL12405273 | 0.86 | HDAC1 (0.36) | HDAC1HDAC6GRM5RORCAR | |
| SCHEMBL12405566 | 0.86 | GRM5 (0.37) | HDAC1HDAC6GRM5RORC | |
| SCHEMBL12404723 | 0.86 | HDAC1 (0.38) | HDAC1HDAC6GRM5RENAR | |
| SCHEMBL13212378 | 0.85 | PIK3CD (0.42) | HDAC1HDAC6GRM5RORCNCF1 | |
| SCHEMBL12405640 | 0.84 | SLC22A12 (0.38) | HDAC1HDAC6GRM5RORCAR | |
| SCHEMBL12404722 | 0.83 | NPY5R (0.39) | HDAC1HDAC6GRM5 | |
| SCHEMBL12404728 | 0.83 | HDAC1 (0.38) | HDAC1HDAC6GRM5REN | |
| SCHEMBL12404726 | 0.83 | HDAC1 (0.38) | HDAC1HDAC6GRM5 | |
| SCHEMBL12404736 | 0.83 | HDAC1 (0.52) | HDAC1HDAC6GRM5AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-08 | — | — | US | disclosed |
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-08 | — | — | US | disclosed |
| US-7700592-B2 | α2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700592-B2 | α2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2008100463-A1 | 3,4-DIHYDR0-L,4-BENZ0XAZINE, 3, 4-DIHYDR0-1, 4-BENZOTHIAZINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007024949-A2 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRA2A | HDAC1 3568/4885HDAC6 3293/4885GRM5 547/4885 |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | HDAC1 3568/4885HDAC6 3293/4885GRM5 547/4885 |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | HDAC1 3568/4885HDAC6 3293/4885GRM5 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.